Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
6.44
+0.41 (6.80%)
At close: May 8, 2026, 4:00 PM EDT
6.24
-0.20 (-3.11%)
After-hours: May 8, 2026, 7:59 PM EDT
Aligos Therapeutics Revenue
Aligos Therapeutics had revenue of $2.83M in the quarter ending March 31, 2026, with 809.97% growth. This brings the company's revenue in the last twelve months to $4.71M, up 43.88% year-over-year. In the year 2025, Aligos Therapeutics had annual revenue of $2.19M, down -44.59%.
Revenue (ttm)
$4.71M
Revenue Growth
+43.88%
P/S Ratio
8.47
Revenue / Employee
$57,378
Employees
82
Market Cap
39.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.19M | -1.76M | -44.59% |
| Dec 31, 2024 | 3.95M | -11.58M | -74.60% |
| Dec 31, 2023 | 15.53M | 1.62M | 11.66% |
| Dec 31, 2022 | 13.91M | 9.55M | 219.04% |
| Dec 31, 2021 | 4.36M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veru Inc. | 16.89M |
| Palatin Technologies | 8.96M |
| Apollomics | 8.84M |
| CervoMed | 4.01M |
| RenovoRx | 1.12M |
| Mereo BioPharma Group | 500.00K |
| Actinium Pharmaceuticals | 90.00K |
| INmune Bio | 50.00K |
ALGS News
- 1 day ago - Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - GlobeNewsWire
- 8 days ago - Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 - GlobeNewsWire
- 15 days ago - Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Aligos Therapeutics signs license deal to develop pevifoscorvir in China - TheFly
- 23 days ago - Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection - GlobeNewsWire
- 24 days ago - Aligos reports first interim analysis of B-SUPREME study, fast track designation - TheFly
- 24 days ago - Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation - GlobeNewsWire
- 6 weeks ago - Aligos Therapeutics initiated with a Buy at WestPark Capital - TheFly